Skip to main content
. 2020 Jul 13;14(10):2646–2659. doi: 10.1002/1878-0261.12745

Fig. 4.

Fig. 4

Diagnostic power of EV‐LINC00853 in all‐stage and early‐stage HCC. (A) AUROCs for discriminating patients with all‐stage HCC from the nontumor subjects (healthy, CH, and LC) (left) and from patients at high risk of developing HCC (CH and LC) (right). (B) AUROCs for discriminating patients with mUICC stage I or II HCC from nontumor subjects (healthy, CH, and LC) (left) and from patients at high risk of developing HCC (CH and LC) (right). (C) AUROCs for discriminating patients with mUICC stage I tumors from the nontumor subjects (healthy, CHs, and LC) (left) and from patients at high risk of developing HCC (CH and LC) (right). Statistically significant differences in AUC were between EV‐LINC00853 and AFP. Target gene expression was calculated relative to that of HMBS.